Abstract
Oxidized low-density lipoprotein (oxLDL) promotes atherosclerosis through a complex interaction of inflammatory and immunologic factors that lead to macrophage lipid uptake and foam cell formation. OxLDL interacts with β2-glycoprotein I (β2GPI) forming oxLDL/β2GPI complexes. These complexes may be formed in the arterial intima during atherogenesis and released into the circulation. Autoantibodies against oxLDL/β2GPI complexes have been demonstrated in patients with systemic lupus erythematosus and/or antiphospholipid syndrome, and shown to be significantly associated with arterial thrombosis. The observation that monoclonal autoantibodies against oxLDL/β2GPI complexes significantly increased the oxLDL uptake by macrophages strongly suggests that such IgG autoantibodies are pro-atherogenic. In this article, we review the recent progress in our understanding of LDL oxidation, oxLDL/β2GPI complex formation, and immune regulation of atherogenesis.
| Original language | English |
|---|---|
| Pages (from-to) | 12-19 |
| Number of pages | 8 |
| Journal | Clinical Reviews in Allergy and Immunology |
| Volume | 37 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Antiphospholipid antibodies
- Atherosclerosis
- Autoimmunity
- Oxidized LDL
- β2GPI
ASJC Scopus subject areas
- Immunology and Allergy
- Medicine(all)
Cite this
Immunogenic oxidized low-density lipoprotein/β2-glycoprotein I complexes in the diagnostic management of atherosclerosis. / Lopez, Luis R.; Kobayashi, Kazuko; Matsunami, Yukana; Matsuura, Eiji.
In: Clinical Reviews in Allergy and Immunology, Vol. 37, No. 1, 2009, p. 12-19.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunogenic oxidized low-density lipoprotein/β2-glycoprotein I complexes in the diagnostic management of atherosclerosis
AU - Lopez, Luis R.
AU - Kobayashi, Kazuko
AU - Matsunami, Yukana
AU - Matsuura, Eiji
PY - 2009
Y1 - 2009
N2 - Oxidized low-density lipoprotein (oxLDL) promotes atherosclerosis through a complex interaction of inflammatory and immunologic factors that lead to macrophage lipid uptake and foam cell formation. OxLDL interacts with β2-glycoprotein I (β2GPI) forming oxLDL/β2GPI complexes. These complexes may be formed in the arterial intima during atherogenesis and released into the circulation. Autoantibodies against oxLDL/β2GPI complexes have been demonstrated in patients with systemic lupus erythematosus and/or antiphospholipid syndrome, and shown to be significantly associated with arterial thrombosis. The observation that monoclonal autoantibodies against oxLDL/β2GPI complexes significantly increased the oxLDL uptake by macrophages strongly suggests that such IgG autoantibodies are pro-atherogenic. In this article, we review the recent progress in our understanding of LDL oxidation, oxLDL/β2GPI complex formation, and immune regulation of atherogenesis.
AB - Oxidized low-density lipoprotein (oxLDL) promotes atherosclerosis through a complex interaction of inflammatory and immunologic factors that lead to macrophage lipid uptake and foam cell formation. OxLDL interacts with β2-glycoprotein I (β2GPI) forming oxLDL/β2GPI complexes. These complexes may be formed in the arterial intima during atherogenesis and released into the circulation. Autoantibodies against oxLDL/β2GPI complexes have been demonstrated in patients with systemic lupus erythematosus and/or antiphospholipid syndrome, and shown to be significantly associated with arterial thrombosis. The observation that monoclonal autoantibodies against oxLDL/β2GPI complexes significantly increased the oxLDL uptake by macrophages strongly suggests that such IgG autoantibodies are pro-atherogenic. In this article, we review the recent progress in our understanding of LDL oxidation, oxLDL/β2GPI complex formation, and immune regulation of atherogenesis.
KW - Antiphospholipid antibodies
KW - Atherosclerosis
KW - Autoimmunity
KW - Oxidized LDL
KW - β2GPI
UR - http://www.scopus.com/inward/record.url?scp=70350436671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350436671&partnerID=8YFLogxK
U2 - 10.1007/s12016-008-8096-8
DO - 10.1007/s12016-008-8096-8
M3 - Article
C2 - 18982458
AN - SCOPUS:70350436671
VL - 37
SP - 12
EP - 19
JO - Clinical Reviews in Allergy and Immunology
JF - Clinical Reviews in Allergy and Immunology
SN - 1080-0549
IS - 1
ER -